Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors

Journal of Molecular Biology

Volumn 426, Issue 13, 2014, Pages 2457-2470

  Canning, Peter ^a   Tan, Li ^b   Chu, Kiki ^b   Lee, Sam W ^b   Gray, Nathanael S ^b   Bullock, Alex N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

crystallography; drug design; gleevec; oncology; phosphorylation

Indexed keywords

ABELSON KINASE; DISCOIDIN; DISCOIDIN DOMAIN RECEPTOR 1; IMATINIB; PONATINIB; UNCLASSIFIED DRUG;

ALPHA HELIX; ARTICLE; CANCER INHIBITION; CONFORMATION; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; HYDROPHOBICITY; IC 50; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STABILITY;

CRYSTALLOGRAPHY; DRUG DESIGN; GLEEVEC; ONCOLOGY; PHOSPHORYLATION;

AMINO ACID SEQUENCE; BENZAMIDES; BINDING SITES; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ABL; PYRIDAZINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, COLLAGEN; RECEPTORS, MITOGEN; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84901804479     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2014.04.014     Document Type: Article

References (63)

1. W. Vogel, G.D. Gish, F. Alves, and T. Pawson The discoidin domain receptor tyrosine kinases are activated by collagen Mol Cell 1 1997 13 23 (Pubitemid 127376389)
2. A. Shrivastava, C. Radziejewski, E. Campbell, L. Kovac, M. McGlynn, and T.E. Ryan et al. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors Mol Cell 1 1997 25 34 (Pubitemid 127376390)
3. O. Ichikawa, M. Osawa, N. Nishida, N. Goshima, N. Nomura, and I. Shimada Structural basis of the collagen-binding mode of discoidin domain receptor 2 EMBO J 26 2007 4168 4176 (Pubitemid 47462092)
4. B. Leitinger Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2. Identification of collagen binding sites in DDR2 J Biol Chem 278 2003 16761 16769 (Pubitemid 36799543)
5. F. Carafoli, D. Bihan, S. Stathopoulos, A.D. Konitsiotis, M. Kvansakul, and R.W. Farndale et al. Crystallographic insight into collagen recognition by discoidin domain receptor 2 Structure 17 2009 1573 1581
6. N.A. Noordeen, F. Carafoli, E. Hohenester, M.A. Horton, and B. Leitinger A transmembrane leucine zipper is required for activation of the dimeric receptor tyrosine kinase DDR1 J Biol Chem 281 2006 22744 22751
7. C. Mihai, M. Chotani, T.S. Elton, and G. Agarwal Mapping of DDR1 distribution and oligomerization on the cell surface by FRET microscopy J Mol Biol 385 2009 432 445
8. R. Abdulhussein, D.H. Koo, and W.F. Vogel Identification of disulfide-linked dimers of the receptor tyrosine kinase DDR1 J Biol Chem 283 2008 12026 12033
9. W.F. Vogel, R. Abdulhussein, and C.E. Ford Sensing extracellular matrix: an update on discoidin domain receptor function Cell Signalling 18 2006 1108 1116 (Pubitemid 43674043)
10. W.F. Vogel, A. Aszodi, F. Alves, and T. Pawson Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development Mol Cell Biol 21 2001 2906 2917 (Pubitemid 32244933)
11. J.P. Labrador, V. Azcoitia, J. Tuckermann, C. Lin, E. Olaso, and S. Manes et al. The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism EMBO Rep 2 2001 446 452 (Pubitemid 32519565)
12. R.R. Valiathan, M. Marco, B. Leitinger, C.G. Kleer, and R. Fridman Discoidin domain receptor tyrosine kinases: new players in cancer progression Cancer Metastasis Rev 31 2012 295 321
13. C. Franco, G. Hou, P.J. Ahmad, E.Y. Fu, L. Koh, and W.F. Vogel et al. Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice Circ Res 102 2008 1202 1211
14. S.H. Yang, H.A. Baek, H.J. Lee, H.S. Park, K.Y. Jang, and M.J. Kang et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas Oncol Rep 24 2010 311 319
15. T. Ren, J. Zhang, X. Liu, and L. Yao Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients Med Oncol 30 2013 397
16. J. Quan, T. Yahata, S. Adachi, K. Yoshihara, and K. Tanaka Identification of receptor tyrosine kinase, discoidin domain receptor 1 (DDR1), as a potential biomarker for serous ovarian cancer Int J Mol Sci 12 2011 971 982
17. K. Shimada, M. Nakamura, E. Ishida, T. Higuchi, H. Yamamoto, and K. Tsujikawa et al. Prostate cancer antigen-1 contributes to cell survival and invasion though discoidin receptor 1 in human prostate cancer Cancer Sci 99 2008 39 45 (Pubitemid 350239029)
18. D. Yoshida, and A. Teramoto Enhancement of pituitary adenoma cell invasion and adhesion is mediated by discoidin domain receptor-1 J Neuro Oncol 82 2007 29 40
19. H.S. Park, K.R. Kim, H.J. Lee, H.N. Choi, D.K. Kim, and B.T. Kim et al. Overexpression of discoidin domain receptor 1 increases the migration and invasion of hepatocellular carcinoma cells in association with matrix metalloproteinase Oncol Rep 18 2007 1435 1441
20. P.S. Hammerman, M.L. Sos, A.H. Ramos, C. Xu, A. Dutt, and W. Zhou et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discov 1 2011 78 89
21. K. Zhang, C.A. Corsa, S.M. Ponik, J.L. Prior, D. Piwnica-Worms, and K.W. Eliceiri et al. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis Nat Cell Biol 15 2013 677 687
22. K. Valencia, C. Ormazabal, C. Zandueta, D. Luis-Ravelo, I. Anton, and M.J. Pajares et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis Clin Cancer Res 18 2012 969 980
23. O. Gross, R. Girgert, B. Beirowski, M. Kretzler, H.G. Kang, and J. Kruegel et al. Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease Matrix Biol 29 2010 346 356
24. D. Guerrot, M. Kerroch, S. Placier, S. Vandermeersch, C. Trivin, and M. Mael-Ainin et al. Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy Am J Pathol 179 2011 83 91
25. C. Avivi-Green, M. Singal, and W.F. Vogel Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis Am J Respir Crit Care Med 174 2006 420 427 (Pubitemid 44223123)
26. B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, and N. Gattermann et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417 (Pubitemid 44903745)
27. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
28. M. Bantscheff, D. Eberhard, Y. Abraham, S. Bastuck, M. Boesche, and S. Hobson et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat Biotechnol 25 2007 1035 1044 (Pubitemid 47517638)
29. P.P. Ongusaha, J.I. Kim, L. Fang, T.W. Wong, G.D. Yancopoulos, and S.A. Aaronson et al. p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop EMBO J 22 2003 1289 1301 (Pubitemid 36362693)
30. E. Day, B. Waters, K. Spiegel, T. Alnadaf, P.W. Manley, and E. Buchdunger et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib Eur J Pharm 599 2008 44 53
31. A. Akhmetshina, P. Venalis, C. Dees, N. Busch, J. Zwerina, and G. Schett et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis Arthritis Rheum 60 2009 219 224
32. C.E. Daniels, M.C. Wilkes, M. Edens, T.J. Kottom, S.J. Murphy, and A.H. Limper et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis J Clin Invest 114 2004 1308 1316 (Pubitemid 40385302)
33. T. O'Hare, W.C. Shakespeare, X. Zhu, C.A. Eide, V.M. Rivera, and F. Wang et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 16 2009 401 412
34. J.M. Goldman Ponatinib for chronic myeloid leukemia N Engl J Med 367 2012 2148 2149
35. H.G. Kim, L. Tan, E.L. Weisberg, F. Liu, P. Canning, and H.G. Choi et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor ACS Chem Biol 8 2013 2145 2150
36. F. Carafoli, M.C. Mayer, K. Shiraishi, M.A. Pecheva, L.Y. Chan, and R. Nan et al. Structure of the discoidin domain receptor 1 extracellular region bound to an inhibitory Fab fragment reveals features important for signaling Structure 20 2012 688 697
37. T. Bertrand, M. Kothe, J. Liu, A. Dupuy, A. Rak, and P.F. Berne et al. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition J Mol Biol 423 2012 439 453
38. S.W. Cowan-Jacob, G. Fendrich, A. Floersheimer, P. Furet, J. Liebetanz, and G. Rummel et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia Acta Crystallogr Sect D Biol Crystallogr 63 2007 80 93 (Pubitemid 46141483)
39. S. Munshi, D.L. Hall, M. Kornienko, P.L. Darke, and L.C. Kuo Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 Å resolution Acta Crystallogr Sect D Biol Crystallogr 59 2003 1725 1730 (Pubitemid 37245124)
40. S. Favelyukis, J.H. Till, S.R. Hubbard, and W.T. Miller Structure and autoregulation of the insulin-like growth factor 1 receptor kinase Nat Struct Biol 8 2001 1058 1063 (Pubitemid 33101627)
41. J.H. Till, M. Becerra, A. Watty, Y. Lu, Y. Ma, and T.A. Neubert et al. Crystal structure of the MuSK tyrosine kinase: insights into receptor autoregulation Structure 10 2002 1187 1196 (Pubitemid 35254007)
42. C.S. Lebakken, S.M. Riddle, U. Singh, W.J. Frazee, H.C. Eliason, and Y. Gao et al. Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform J Biomol Screening 14 2009 924 935
43. C.D. Mol, D.R. Dougan, T.R. Schneider, R.J. Skene, M.L. Kraus, and D.N. Scheibe et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase J Biol Chem 279 2004 31655 31663 (Pubitemid 39037836)
44. M. Gao, L. Duan, J. Luo, L. Zhang, X. Lu, and Y. Zhang et al. Discovery and optimization of 3-(2-(pyrazolo[1,5-A]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors J Med Chem 56 2013 3281 3295
45. S.B. Yan, V.L. Peek, R. Ajamie, S.G. Buchanan, J.R. Graff, and S.A. Heidler et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models Invest New Drugs 31 2013 833 844
46. R. Capdeville, E. Buchdunger, J. Zimmermann, and A. Matter Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat Rev Drug Discov 1 2002 493 502
47. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat Rev Cancer 9 2009 28 39
48. F. Grimminger, R.T. Schermuly, and H.A. Ghofrani Targeting non-malignant disorders with tyrosine kinase inhibitors Nat Rev Drug Discov 9 2010 956 970
49. V. Pitini, C. Arrigo, C. Di Mirto, P. Mondello, and G. Altavilla Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia Lung Cancer 82 2013 171 172
50. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, and P.N. Rao et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880 (Pubitemid 32743979)
51. W. Kabsch Xds Acta Crystallogr Sect D Biol Crystallogr 66 2010 125 132
52. P. Evans Scaling and assessment of data quality Acta Crystallogr Sect D Biol Crystallogr 62 2006 72 82
53. P.R. Evans An introduction to data reduction: space-group determination, scaling and intensity statistics Acta Crystallogr Sect D Biol Crystallogr 67 2011 282 292
54. M.D. Winn, C.C. Ballard, K.D. Cowtan, E.J. Dodson, P. Emsley, and P.R. Evans et al. Overview of the CCP4 suite and current developments Acta Crystallogr Sect D Biol Crystallogr 67 2011 235 242
55. A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, and R.J. Read Phaser crystallographic software J Appl Crystallogr 40 2007 658 674 (Pubitemid 47080256)
56. P.D. Adams, P.V. Afonine, G. Bunkoczi, V.B. Chen, I.W. Davis, and N. Echols et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr Sect D Biol Crystallogr 66 2010 213 221
57. G.N. Murshudov, P. Skubak, A.A. Lebedev, N.S. Pannu, R.A. Steiner, and R.A. Nicholls et al. REFMAC5 for the refinement of macromolecular crystal structures Acta Crystallogr Sect D Biol Crystallogr 67 2011 355 367
58. P. Emsley, B. Lohkamp, W.G. Scott, and K. Cowtan Features and development of Coot Acta Crystallogr Sect D Biol Crystallogr 66 2010 486 501
59. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr Sect D Biol Crystallogr 60 2004 2126 2132 (Pubitemid 41742764)
60. J. Painter, and E.A. Merritt Optimal description of a protein structure in terms of multiple groups undergoing TLS motion Acta Crystallogr Sect D Biol Crystallogr 62 2006 439 450
61. V.B. Chen, W.B. Arendall, J.J. Headd, D.A. Keedy, R.M. Immormino, and G.J. Kapral et al. MolProbity: all-Atom structure validation for macromolecular crystallography Acta Crystallogr Sect D Biol Crystallogr 66 2010 12 21
62. H. Yang, V. Guranovic, S. Dutta, Z. Feng, H.M. Berman, and J.D. Westbrook Automated and accurate deposition of structures solved by X-ray diffraction to the Protein Data Bank Acta Crystallogr Sect D Biol Crystallogr 60 2004 1833 1839 (Pubitemid 41079705)
63. Schrödinger LLC. (version 1.2r3pre). The PyMOL Molecular Graphics System.